Kazia Doses First Patient In Phase 2 PNOC035 Study Of Paxalisib In Pediatric Brain Cancer; Stock Up

Kazia Therapeutics announced that the first patient has been dosed in Arm A of PNOC035, a Phase 2 platform study of lead oncology asset paxalisib combined with gemcitabine. The trial is evaluating the regimen in patients aged 1 to 39, marking a clinical-development milestone for paxalisib but providing no efficacy or financial data.